. . . according to the findings of the Ultra-Low-dose Transdermal Estradiol Assessment, a randomized, blinded, placebo-controlled, 2-year trial involving about 400 postmenopausal women.
. . . according to the findings of the Ultra-Low-dose Transdermal Estradiol Assessment, a randomized, blinded, placebo-controlled, 2-year trial involving about 400 postmenopausal women.
The authors of the study gave the women, who had no history of breast cancer or hysterectomy, either unopposed 0.014 mg/d transdermal estradiol or an identical placebo patch.
The finding of no significant difference between treatment groups in change in percent breast density after 1 year (between-group difference, 0.1%; 95% CI, –1.3%–1.6%) or 2 years of treatment (0.8%; –0.6%–2.1%) is significant because women with high breast density are at already increased risk for breast cancer. And interventions like combination estrogen/medroxy-progesterone that further increase breast density can put women at unacceptable risk. The ultra-low-dose transdermal estradiol also improved bone density and had no negative effects on the uterus.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More